STEP I: Sexually active males must be willing to use a condom (even if they have undergone a prior vasectomy) while having intercourse, while taking lenalidomide and for 28 days after stopping lenalidomide; male subjects must also agree to abstain from donating blood, semen, or sperm during study participation and for at least 28 days after discontinuation from lenalidomide; male subjects must be willing to use condoms for 90 days after discontinuation of carfilzomibXx_NEWLINE_xXSTEP II: Sexually active males must be willing to use a condom (even if they have undergone a prior vasectomy) while having intercourse, while taking lenalidomide and for 28 days after stopping lenalidomide; male subjects must also agree to abstain from donating blood, semen, or sperm during study participation and for at least 28 days after discontinuation from lenalidomide; males must agree to use contraception and agree to not donate sperm for at least 90 days after the last day of carfilzomibXx_NEWLINE_xXPatients must not have any prior treatment with any PI3K inhibitor, or lenalidomideXx_NEWLINE_xXProgression on lenalidomide as part of first line therapy (lenalidomide-refractory disease)\r\n* Lenalidomide-refractory disease is defined as disease progression on or progression within 60 days of the last dose of a lenalidomide-based treatment; patients should have received at least 2 cycles of a lenalidomide-based regimen to be evaluable for refractoriness; examples: 1) progression on lenalidomide maintenance therapy after initial induction +/- consolidation; 2) initial response followed by progression on continuous lenalidomide-dexamethasone +/- elotuzumab or daratumumabXx_NEWLINE_xXPhase I (dose escalation and \pre-treated\ expansion cohort only): refractory to or not amenable or eligible for established MDS therapy (HMA, lenalidomide)Xx_NEWLINE_xXPhase I (\untreated\ expansion cohort only): no prior HMA and/or lenalidomide treatment Patient has the evidence of symptomatic anemia according to the following criteria:Xx_NEWLINE_xXConcurrent enrollment in another therapeutic investigational study or have previously taken ibrutinib and/or lenalidomide.Xx_NEWLINE_xXA regimen that included an immunomodulatory agent (eg, thalidomide, lenalidomide, pomalidomide) and a proteasome inhibitor (eg, bortezomib, carfilzomib, ixazomib), either alone or in combinationXx_NEWLINE_xXLenalidomide: 7 daysXx_NEWLINE_xXReceived >6 cycles lifetime exposure to Lenalidomide.Xx_NEWLINE_xXPlans to receive maintenance treatment within 100 days post-engraftment (e.g. Lenalidomide, Bortezomib, Pomalidomide, Thalidomide, Carfilzomib, etc.)Xx_NEWLINE_xXTreatment within 30 days prior to enrollment/randomization with strong immune modulators including but not limited to systemic cyclosporine, tacrolimus, sirolimus, mycophenolate mofetil, methotrexate, azathioprine, rapamycin, thalidomide, and lenalidomideXx_NEWLINE_xXImmunomodulator therapy (IMiD e.g. lenalidomide or thalidomide) -1 weekXx_NEWLINE_xXReceived 2-4 prior lines of therapy, including lenalidomide and a PI, either sequential or in the same line, and is refractory (relapsed and refractory or refractory) to lenalidomide in the last line. Refractory status to lenalidomide is defined as progression while on lenalidomide therapy or within 60 days of last dose, following at least 2 cycles of lenalidomide with at least 14 doses of lenalidomide per cycle.Xx_NEWLINE_xXPatients not able to tolerate lenalidomide or carfilzomib or dexamethasoneXx_NEWLINE_xXPatients with 5q del MDS unless failed on Revlimid (lenalidomide)Xx_NEWLINE_xXARM 3: Must have had at least 1 but no more than 3 prior lines of anti-myeloma therapy; exposure to carfilzomib and lenalidomide is allowed but must not be refractory to either drug; must be 6 months from prior therapeutic lenalidomide (> 4 weeks if lenalidomide used as maintenance [dose < 15 mg]) and ?8 weeks from prior carfilzomibXx_NEWLINE_xXAll subjects must have failed 1+ prior treatment, one of which must include lenalidomide therapy\r\n* Patients requiring second (2nd) line of therapy must meet criteria of lenalidomide-refractory disease defined as a history of progression on or within 60 days of completion of a regimen of a minimum of 2 cycles containing full or maximally tolerated dose of lenalidomide\r\n** Patients progressing on lenalidomide maintenance in the first line of therapy will be eligible provided that they have received at least 2 cycles of lenalidomide at established standard maintenance dosing schedule; maintenance dosing and schedule must be documented and approved by lead principal investigator prior to enrollment \r\n* For patients requiring third (3rd) or higher line of therapy, history of treatment with lenalidomide is required but lenalidomide-refractory status is not\r\n* In addition, subjects also refractory to pomalidomide, carfilzomib, or bortezomib are permitted limited to 10 subjects per groupXx_NEWLINE_xXHistory of allergy to mannitol or prior hypersensitivity to thalidomide, lenalidomide or pomalidomideXx_NEWLINE_xXAll pts must have received prior lenalidomide therapy and been determined to be refractory, relapsed, or intolerant.Xx_NEWLINE_xXNursing women (lactating females are eligible provided that they agree not to breast feed while taking lenalidomide)Xx_NEWLINE_xXFor Daratumumab + bortezomib + lenalidomide + dexamethasone (D-VRd) and Daratumumab + bortezomib + melphalan + prednisone + dexamethasone (D-VMP) regimen: newly diagnosed myelomaXx_NEWLINE_xXFor Daratumumab + lenalidomide + dexamethasone (D-Rd) regimen: relapsed or refractory diseaseXx_NEWLINE_xXPatients with 5q- syndrome should have failed to respond to or progressed on treatment with lenalidomide, where available and indicatedXx_NEWLINE_xXPrior treatment with lenalidomide; patients previously treated with thalidomide who discontinued treatment for reasons aside from an adverse reaction to thalidomide are permittedXx_NEWLINE_xXKnown hypersensitivity to thalidomide or lenalidomideXx_NEWLINE_xXLenalidomide-related toxicities before ASCT necessitating its discontinuation as part of treatmentXx_NEWLINE_xXPatients must not have received prior therapy with lenalidomide (for more than 2 months) nor eltrombopagXx_NEWLINE_xXAble to take aspirin (81 or 325 mg) daily or for thromboprophylaxis with lenalidomide.Xx_NEWLINE_xXMalabsorption syndrome or other condition that precludes oral route of administration of lenalidomide.Xx_NEWLINE_xXSymptomatic multiple myeloma (MM) having progressed on >= 2 prior therapies including proteasome inhibitor (i.e. bortezomib, carfilzomib ixazomib), immunomodulatory drug (i.e., thalidomide, lenalidomide, pomalidomide), and daratumumab or other CD38 targeting monoclonal antibody. Subjects who are refractory to proteasome inhibitors or ONC201 are eligible. Subjects must not be candidates for treatment regimens known to provide clinical benefit to be eligible for this studyXx_NEWLINE_xXNursing women (lactating females are eligible provided that they agree not to breast feed while taking lenalidomide)Xx_NEWLINE_xXPrior therapy with lenalidomideXx_NEWLINE_xXPatients who previously received lenalidomide and have experienced toxicities resulting in treatment discontinuation.Xx_NEWLINE_xXPatients who experienced thromboembolic events while on full anticoagulation during prior therapy with lenalidomide or thalidomide.Xx_NEWLINE_xXPrior treatment with lenalidomide within 8 weeks prior to entering the studyXx_NEWLINE_xXInclusion Criteria:\n\n        Patients fulfilling the following criteria will be eligible to provide continued long-term\n        follow-up data as part of this study:\n\n          1. Enrolled and randomized on the BMT CTN 0702 protocol.\n\n          2. Alive at the completion of BMT CTN 0702 protocol specified follow-up defined as 4\n             years post-randomization.\n\n          3. Patients without evidence of disease progression at the completion of BMT CTN 0702\n             protocol specified follow up.\n\n          4. Signed Informed Consent Form.\n\n          5. Patients with the ability to speak English or Spanish are eligible to participate in\n             the HQL component of this trial.\n\n        Inclusion Criteria for Optional Long-term Lenalidomide Maintenance Therapy:\n\n        Patients fulfilling the following criteria will be eligible to provide continued long-term\n        follow-up data AND receive long-term lenalidomide maintenance therapy as part of this\n        study:\n\n          1. Enrolled and randomized to BMT CTN 0702.\n\n          2. Completion of 3 years of maintenance therapy on BMT CTN 0702.\n\n          3. Registered in the mandatory Revlimid REMS® program (formerly the RevAssist® for Study\n             Participants (RASP) program), and be willing and able to comply with the requirements\n             of the Revlimid REMS® program, including counseling, pregnancy testing, and phone\n             surveys.\n\n          4. Signed informed consent form.\n\n          5. Patients with the ability to speak English or Spanish are eligible to participate in\n             the HQL component of this trial.\n\n        Exclusion Criteria:\n\n        Patients who meet any of the following criteria will be ineligible to receive long-term\n        lenalidomide maintenance therapy as part of this study:\n\n          1. Patients who have evidence of disease progression prior to enrollment.\n\n          2. Patients who were discontinued from BMT CTN 0702 lenalidomide maintenance therapy, for\n             any reason, prior to the completion of the 3 years of 0702 maintenance.\n\n          3. Female patients who are pregnant (positive - Beta Human Chorionic Gonadotropin) or\n             breastfeeding.\n\n          4. Females of childbearing potential (FCBP) or men who have sexual contact with FCBP\n             unwilling to use contraceptive techniques during the length of lenalidomide\n             maintenance therapy.\n\n          5. Patients who experienced thromboembolic events while on full anticoagulation during\n             prior therapy with lenalidomide.\n\n          6. Patients unwilling to take Deep Vein Thrombosis (DVT) prophylaxis.\n\n          7. Patients who developed a second primary malignancy, excluding non-melanoma skin\n             cancers after initiation of lenalidomide maintenance therapy on BMT CTN 0702.Xx_NEWLINE_xXHistory of allergic reaction (including erythema nodosum) to lenalidomideXx_NEWLINE_xXRelapsed or refractory MM after adequate exposure to and therapeutic response (following IMWG response criteria) to at least one line of treatment with one or more active agents, including alkylating drugs, corticosteroids, immunomodulatory drugs (IMiD: thalidomide, lenalidomide, pomalidomide), proteasome inhibitors (bortezomib, cartilzomib), and monoclonal antibodies (daratumumab, elotuzumab, ixazomab);Xx_NEWLINE_xXHas previous treatment for higher-risk myelodysplastic syndromes (HR MDS) or low-blast AML with chemotherapy or other antineoplastic agents including hypomethylating agent (HMAs) such as decitabine or azacitidine. Previous treatment is permitted with hydroxyurea and with lenalidomide, except that lenalidomide may not be given within 8 weeks before the first dose of study drug.Xx_NEWLINE_xXMust have received at least 3 prior lines of therapy to include treatment with a proteasome inhibitor (eg, bortezomib, carfilzomib, or ixazomib) and an immunomodulatory agent (eg, lenalidomide, pomalidomide) unless double-refractory to both; and a hematopoietic stem cell transplant (HSCT), for those subjects considered HSCT-eligible.Xx_NEWLINE_xXAny prior treatment with pomalidomide. Subjects who have prior treatment with other immunomodulatory compounds (thalidomide, lenalidomide) ARE eligible if they meet all other eligibility criteria and did not have allergic reactions or other \significant toxicity\ per Investigator discretion associated with lenalidomide or thalidomide use.Xx_NEWLINE_xXMust be refractory to lenalidomide, defined as having received at least 2 consecutive cycles of lenalidomide as a single agent or within a lenalidomide-containing regimen and having had PD during treatment with or within 60 days after the last dose of lenalidomide. The starting dose of lenalidomide should have been 25 mg (or as low as 10 mg in the case of renal function impairment or other safety concern), and the final dose should have been a minimum of 10 mg.Xx_NEWLINE_xXPatients who previously had any intolerance to lenalidomide 10 mg or who have a contraindication to lenalidomide will not be eligible for concomitant treatment with lenalidomide but will remain eligible for CAR T cell therapy without lenalidomideXx_NEWLINE_xXAll participants who are prescribed lenalidomide or pomalidomide must be counseled at a minimum of every 21-28 days about pregnancy precautions and risks of fetal exposure (Cohorts B, C, E, F)Xx_NEWLINE_xXHypersensitivity to nivolumab or lenalidomide or any of their excipientsXx_NEWLINE_xXHas progressed on prior therapy with lenalidomideXx_NEWLINE_xXPatients may have received treatment (e.g. azacitidine/decitabine, lenalidomide, growth factors) for antecedent low-grade myeloid neoplasmXx_NEWLINE_xXLenalidomide, thalidomide or other immunomodulatory drugs (IMiDs)Xx_NEWLINE_xXPrior venetoclax or other BCL-2 family inhibitors or prior lenalidomide is not permittedXx_NEWLINE_xXNewly diagnosed, previously untreated myeloma requiring systemic chemotherapy\r\n* Prior treatment of hypercalcemia or spinal cord compression or active and/or aggressively progressing myeloma with corticosteroids and/or lenalidomide and/or bortezomib/principal investigator (PI)-based regimens does not disqualify the subject (the corticosteroid treatment dose should not exceed the equivalent of 160 mg of dexamethasone in a 4 week period or not more than 1 cycle of lenalidomide and/or PI-based therapy)Xx_NEWLINE_xXSubjects not able to tolerate elotuzumab, lenalidomide, carfilzomib, or dexamethasoneXx_NEWLINE_xXCurrently using lenalidomide or hypomethylating agents (HMA)Xx_NEWLINE_xXHistory of hypersensitivity reactions attributed to thalidomide, lenalidomide, or pomalidomide, including prior development of erythema nodosum if characterized by a desquamating rash while taking thalidomide, lenalidomide, or pomalidomideXx_NEWLINE_xXBreast feeding (if lactating, must agree not to breast feed while taking lenalidomide); breastfeeding should be discontinued if the mother is treated with lenalidomideXx_NEWLINE_xXHave a contraindication to post-ASCT maintenance lenalidomideXx_NEWLINE_xXPatient must have a diagnosis of symptomatic multiple myeloma, who relapses or is refractory after previous treatment with a proteasome inhibitor (bortezomib or carfilzomib) and an immunomodulatory agent (thalidomide, lenalidomide or pomalidomide)Xx_NEWLINE_xXSubject has received > 6 months of lenalidomide (Revlimid) therapy prior to stem cell collectionXx_NEWLINE_xXPrior lenalidomide exposure is permitted only if the subject did not discontinue lenalidomide due to a related, grade >= 3 adverse event (AE)Xx_NEWLINE_xXPrior therapy with elotuzumab or any immunomodulatory drug (IMiD) (including pomalidomide), except for prior thalidomide or lenalidomide (as defined in inclusion criteria)Xx_NEWLINE_xXKnown hypersensitivity to lenalidomide or thalidomide, ibrutinib, rituximab, etoposide, vincristine,\r\ndoxorubicin, cyclophosphamide, or prednisoneXx_NEWLINE_xXPatients with history prior to transplant of progression on lenalidomide therapyXx_NEWLINE_xXHistory of hypersensitivity of lenalidomide or thalidomideXx_NEWLINE_xXPatients with history of previous immunomodulatory therapy (not including lenalidomide or thalidomide)Xx_NEWLINE_xXMust have failed prior anti-myeloma treatments that have included an immunomodulatory drug (IMiD) (pomalidomide, lenalidomide, or thalidomide) AND proteasome inhibitor (bortezomib, carfilzomib, or ixazomib) alone or in combination DLBCL Participants:Xx_NEWLINE_xXAnticoagulants < 7 days prior to Day 1. Aspirin is permitted in Phase 1b per standard of care with lenalidomide-based therapy.Xx_NEWLINE_xXHistory of hypersensitivity to lenalidomide (Part B only)Xx_NEWLINE_xXLenalidomide, thalidomide and pomalidomideXx_NEWLINE_xXPatients who completed induction treatment followed by autologous stem cell transplant as initial therapy for symptomatic myeloma as per IMWG criteria and are considered for single agent lenalidomide (Revlimid) maintenance or initiated single agent Revlimid maintenance\r\n* Patients will be eligible for enrollment in the first 0-4 months of lenalidomide maintenance provided that lenalidomide maintenance has been initiated on days 60 - 120 after transplant\r\n* Patients must be receiving lenalidomide 10 mg or 15 mg and be able to tolerate dose escalation to 25 mg daily\r\n* Patients receiving lenalidomide maintenance cannot exceed 4 months of lenalidomide post-transplantXx_NEWLINE_xXNo evidence of progressive disease on lenalidomideXx_NEWLINE_xXEvidence of progressive disease on lenalidomide maintenance as per IMWG criteriaXx_NEWLINE_xXKnown sensitivity to lenalidomide or other thalidomide derivatives or anti cluster of differentiation (CD)20Xx_NEWLINE_xXPrevious treatment with lenalidomide for AMLXx_NEWLINE_xXPatients must be at least 4 weeks from last cytotoxic chemotherapy (including alkylating, anthracyclines, epipodophyllotoxins, and platinum drugs), or immunomodulatory drugs (including lenalidomide or pomalidomide, or related derivatives) at time of treatment on this protocolXx_NEWLINE_xXKnown hypersensitivity to thalidomide or lenalidomideXx_NEWLINE_xXKnown hypersensitivity to thalidomide, lenalidomide or ipilimumabXx_NEWLINE_xXAll patients must have received prior lenalidomide therapy and been determined to be refractory; refractory will be defined as a history of progression on a regimen containing full or maximally tolerated dose of lenalidomide administered for a minimum of at least two completed cycles of therapyXx_NEWLINE_xXPrior to enrollment, sites must provide evidence of myeloma progression/relapse and evidence of being refractory to lenalidomide, with start and stop dates of lenalidomide therapy and the most recent treatment regimen, as well as best tumor response to all prior treatment regimensXx_NEWLINE_xXKnown hypersensitivity or desquamating rash to either thalidomide or lenalidomideXx_NEWLINE_xXKnown hypersensitivity to thalidomide, lenalidomide or pomalidomide including prior development of erythema nodosum if characterized by a desquamating rash while taking thalidomide, lenalidomide or pomalidomideXx_NEWLINE_xXKnown hypersensitivity to thalidomide or lenalidomideXx_NEWLINE_xXAny prior use of lenalidomide.Xx_NEWLINE_xXSubject has known hypersensitivity to dexamethasone, clarithromycin, lenalidomide, or thalidomideXx_NEWLINE_xXPatients with known hypersensitivity to lenalidomide and/or rituximabXx_NEWLINE_xXDid not receive chemotherapy (including systemic steroids), immunotherapy (interferon), Imids (thalidomide/lenalidomide), proteasome inhibitors (bortezomib), or radiotherapy for at least 21 days prior to Day 1 of Cycle 1Xx_NEWLINE_xXHas received at least 2 consecutive cycles of lenalidomide and be refractory to lenalidomide, as defined per protocol.Xx_NEWLINE_xXHistory of allergy to or intolerance of ibrutinib or lenalidomideXx_NEWLINE_xXPreviously treated relapsed and refractory multiple myeloma\r\n* Patients must have received at least one prior line of therapy\r\n* Prior therapy must include at least 2 cycles of lenalidomide and at least 2 cycles of a proteasome inhibitor (either in separate regimens or within the same regimen)\r\n* Patients must be refractory and/or relapsed/refractory to lenalidomide or prior lenalidomide\r\n* Disease progression on or within 60 days of completion of last therapyXx_NEWLINE_xXHypersensitivity to thalidomide, lenalidomide, pomalidomide, bortezomib, or dexamethasone (such as Stevens-Johnson syndrome); rash to immunomodulatory drug that can be medically managed is allowableXx_NEWLINE_xXDiagnosis of relapsed or relapsed and refractory multiple myeloma following at least 2 prior therapies which must include at least one immunomodulatory drug (e.g., thalidomide, lenalidomide or pomalidomide) and one proteasome inhibitor (e.g., bortezomib or carfilzomib). Patients must not be candidates for regimens known to provide clinical benefit.Xx_NEWLINE_xXHistory of erythema multiforme or severe hypersensitivity to prior IMiD’s such as thalidomide and lenalidomideXx_NEWLINE_xXPatients must have previously received lenalidomide and a proteasome inhibitorXx_NEWLINE_xXPatients must be lenalidomide failures: disease progression on a prior lenalidomide-based therapy or progression within 60 days of the last dose of a lenalidomide; patients should have received at least 2 cycles of a lenalidomide-based regimen at standard doses to be evaluable for refractoriness; prior intolerance to lenalidomide does not exclude participation in the study except in cases of severe allergic reactionXx_NEWLINE_xXHistory of severe allergic reaction, including erythema nodosum, to lenalidomideXx_NEWLINE_xXPatient must agree to take lenalidomide with low dose dexamethasone as their initial therapyXx_NEWLINE_xXPart B: Diagnosis of MM with relapsed or refractory disease with previous exposure to PI (e.g., bortezomib or carfilzomib), IMiDs (e.g., lenalidomide or pomalidomide), and daratumumab, and refractory (based on IMWG criteria) to their last line of therapyXx_NEWLINE_xXRegarding radiation therapy, time elapsed prior to first dose of lenalidomide:Xx_NEWLINE_xXSubject must be at least 2 months (from first dose of lenalidomide) from stem cell infusion.Xx_NEWLINE_xXSubject must have no evidence of active acute or chronic GVHD (Grade 0) for 4 weeks prior to the first dose of lenalidomide.Xx_NEWLINE_xXSubject has isolated Central Nervous System (CNS) involvement or extramedullary relapse. (Subjects with combined CNS/marrow relapse may be Subject has had prior treatment with cytotoxic chemotherapy within 2 weeks of the first dose of lenalidomide with the exception of hydroxyurea (allowed prior to the first dose of lenalidomide and through Day 14 of Cycle 1) and intrathecal (IT) cytarabine will be administered within 2 weeks prior to administration of lenalidomide.Xx_NEWLINE_xXSubject has had prior treatment with lenalidomide. 7. Subject is pregnant or lactating.Xx_NEWLINE_xXSubject has a prior history of malignancies other than AML unless the subject has been free of the disease for ? 5 years from first dose of lenalidomide.Xx_NEWLINE_xXPatient had received at least two previous therapies including lenalidomide and proteasome inhibitor and have demonstrated disease progression on therapy or after completion of the last therapy.Xx_NEWLINE_xXPrior treatment with azacitidine, decitabine, other hypomethylating agents and lenalidomide ( for lenalidomide : unless the last dose received is >= 8 weeks prior to inclusion into the study).Xx_NEWLINE_xX? 2 prior lines of therapy which must have included at least 2 consecutive cycles of lenalidomide and a proteosome inhibitor alone or in combinationXx_NEWLINE_xXRefractory to proteosome inhibitor and lenalidomide, and to last treatmentXx_NEWLINE_xXPrior anti-myeloma treatments must have included a lenalidomide AND proteasome inhibitor alone or in combination.Xx_NEWLINE_xXHad rash ? Grade 3 during prior thalidomide, lenalidomide, or pomalidomide therapyXx_NEWLINE_xXHas a history of anaphylaxis or hypersensitivity to thalidomide, lenalidomide, POM, or dexXx_NEWLINE_xXFor carfilzomib-lenalidomide-dexamethasone (KRd) regimen: newly diagnosed myeloma. For carfilzomib-dexamethasone (CFZ-dex) regimen: relapsed or refractory diseaseXx_NEWLINE_xXPatients must not have prior therapy with lenalidomideXx_NEWLINE_xXPrior thalidomide is allowed, however, patients must not have prior >= grade-3 allergic reactions to thalidomideXx_NEWLINE_xXEligibility for crossover registration from Arm A (lenalidomide alone) to Arm B (lenalidomide and epoetin alfa):Xx_NEWLINE_xXPatients must have completed 16 weeks of monotherapy with lenalidomideXx_NEWLINE_xXPatients must not have a limiting unresolved grade 3 or greater toxicity from lenalidomide monotherapy or drug intolerance preventing continuation of lenalidomide treatmentXx_NEWLINE_xXAgreement to comply with all local requirements of the lenalidomide risk minimization planXx_NEWLINE_xXHistory of resistance to lenalidomide or response duration of <1 yearXx_NEWLINE_xXHistory of erythema multiforme, Grade >= 3 rash, or blistering following prior treatment with immunomodulatory derivatives such as thalidomide and lenalidomideXx_NEWLINE_xXSubjects with relapsed/refractory MM who have received at least two prior lines of therapy including lenalidomide and either bortezomib or carfilzomib and have demonstrated disease progression on or within 60 days of the completion of the most recent treatment regimen.Xx_NEWLINE_xXMust have undergone prior treatment with at least 2 cycles of lenalidomide and at least 2 cycles of proteasome inhibitor unless not a candidate.Xx_NEWLINE_xXHypersensitivity to thalidomide, lenalidomide, pomalidomide, or dexamethasoneXx_NEWLINE_xXPatients may have received prior lenalidomide as long as it has been at least two years since exposure and the patient may not have experienced a progression while receiving lenalidomide previouslyXx_NEWLINE_xXPrior therapy with lenalidomideXx_NEWLINE_xXPatient has had at least 2 or more prior lines of therapy including lenalidomide and bortezomib and has demonstrated disease progression on or within 60 days of completion of the last therapyXx_NEWLINE_xXPrior treatment with lenalidomideXx_NEWLINE_xXHave currently active gastrointestinal disease, or prior surgery that may affect the ability of the patient to absorb oral lenalidomideXx_NEWLINE_xXPatients must have also undergone prior treatment with at least 2 cycles of lenalidomide and at least 2 cycles of a proteosome inhibitor (either in separate regimens or within the same regimen).Xx_NEWLINE_xXFor MM-2 cohort only: Hypersensitivity (eg, Rash Grade 3 or 4) to thalidomide, lenalidomide, or dexamethasone (MM-2b).Xx_NEWLINE_xXAny prior use of lenalidomideXx_NEWLINE_xXDel(5q) karyotype unless treatment with lenalidomide has failed. Failure is defined as either: 1) having received at least 3 months of lenalidomide treatment without RBC transfusion benefit (International Working Group [IWG] 2006); 2) progression or relapse after hematologic improvement with lenalidomide (IWG 2006); 3) discontinuation of lenalidomide due to toxicity; or 4) unable to receive lenalidomide due to a contraindication. Source documentation for lenalidomide treatment failure must be verified by the sponsorXx_NEWLINE_xXPatients must have received at least 2 prior lines of anti-myeloma therapy, which must include at least 2 consecutive cycles of lenalidomide and a proteasome inhibitor (bortezomib, carfilzomib or ixazomib) given alone or in combination.Xx_NEWLINE_xXPatients must have failed treatment with lenalidomide and a proteasome inhibitor (bortezomib, carfilzomib, or ixazomib) alone or in combination.Xx_NEWLINE_xXPrior use of lenalidomideXx_NEWLINE_xXArm A only: ImiDs (eg, lenalidomide, thalidomide);Xx_NEWLINE_xXSubjects must have received prior treatment with a lenalidomide-containing regimen for at least 2 consecutive cycles (full therapeutic dose) and must have been deemed as relapsed, refractory, or intolerant. Refractory is defined as progressing on-treatment or within 60 days of the last dose.Xx_NEWLINE_xXIf treated with a lenalidomide and dexamethasone combination, progression during the first 3 months after initiating treatment.Xx_NEWLINE_xXAny progression during treatment if the lenalidomide and dexamethasone regimen was the most recent line of therapy.Xx_NEWLINE_xXPatients at least 3 weeks from last cytotoxic chemotherapy; patients may continue tyrosine kinase inhibitors and/or lenalidomide until the day of study consentXx_NEWLINE_xXPatients with known hypersensitivity to lenalidomide and/or rituximab (CD20+ patients only)Xx_NEWLINE_xXPrior use of lenalidomide.Xx_NEWLINE_xXPregnancy tests must occur within 10-14 days and again within 24 hours prior to initiation of cycle 1 of lenalidomide; females of childbearing potential (FCBP) with regular or no menstruation must have a pregnancy test weekly for the first 28 days and then every 28 days while on lenalidomide therapy (including breaks in therapy); at discontinuation of lenalidomide and at day 28 post the last dose of lenalidomide; females with irregular menstruation must have a pregnancy test weekly for the first 28 days and then every 14 days while on lenalidomide therapy (including breaks in therapy), at discontinuation of lenalidomide and at day 14 and day 28 post the last dose of lenalidomideXx_NEWLINE_xXKnown hypersensitivity to thalidomide or lenalidomideXx_NEWLINE_xXThe development of erythema nodosum if characterized by a desquamating rash while taking thalidomide, lenalidomide or similar drugsXx_NEWLINE_xXPrior use of ibrutinib or other BTK inhibitors, rituximab or lenalidomideXx_NEWLINE_xXFemales of childbearing potential must have a negative serum pregnancy test with a minimum sensitivity of 50 mIU/mL and agree to use two medically accepted forms of contraception from the time of initial screening through completion of the study or to practice complete abstinence from heterosexual intercourse during the following time periods related to this study: \r\n* For at least 28 days before starting lenalidomide \r\n* Throughout the entire duration of lenalidomide treatment\r\n* During dose interruptions\r\n* For at least 28 days after lenalidomide discontinuation.Xx_NEWLINE_xXPatients with a prior history of serious allergic reactions associated with thalidomide or lenalidomideXx_NEWLINE_xXPatients who have received pomalidomide in the past are not eligible; patients who have prior treatment with other immunomodulatory drugs (IMiDs) (thalidomide, lenalidomide) ARE eligible if they meet all other eligibility criteria and did not have \significant toxicity\ associated with lenalidomide or thalidomide use; a “significant” toxicity will be defined as one that required a dose reduction or discontinuation due to toxicity; please discuss any questions with the PIXx_NEWLINE_xXPregnant females (lactating females must agree not to breast feed while taking carfilzomib, lenalidomide or romidepsin)Xx_NEWLINE_xXPrior use of lenalidomide if discontinued due to toxicityXx_NEWLINE_xXReceived two lines of prior therapy that includes an immune-related inflammatory disease (IMiD) (lenalidomide or thalidomide) and a proteasome inhibitor (bortezomib and/or carfilzomib) (used either separately or in combination); prior pomalidomide therapy is permitted, provided the patient achieved at least a partial remission and had not progressed for 3 months after stopping therapyXx_NEWLINE_xXKnown hypersensitivity to thalidomide or lenalidomideXx_NEWLINE_xXThe development of erythema nodosum if characterized by a desquamating rash while taking lenalidomideXx_NEWLINE_xXTreatment with chemotherapy, monoclonal antibodies or biological agents (e.g. ibrutinib, lenalidomide) within 28 days prior to entering the studyXx_NEWLINE_xXKnown hypersensitivity to thalidomide or lenalidomideXx_NEWLINE_xXThe development of erythema nodosum if characterized by a desquamating rash while taking thalidomide, lenalidomide or similar drugsXx_NEWLINE_xXPatients must have had therapy with a proteasome inhibitor and lenalidomide and be refractory to lenalidomide according to the International Myeloma Working Group (IMWG) criteria definition of refractory disease (progressive disease on or within 60 days of stopping lenalidomide)Xx_NEWLINE_xXPatients must not have had progression of disease on lenalidomide 25 mg; stable disease on lenalidomide is permittedXx_NEWLINE_xXHistory of allergic reaction (including erythema nodosum) to lenalidomideXx_NEWLINE_xXDisease shows evidence of refractoriness or intolerance to lenalidomide or if previously treated with a lenalidomide-containing regimen the participant is excluded if he or she discontinued due to any adverse event related to prior lenalidomide treatmentXx_NEWLINE_xXHistory of allergic reactions attributed to thalidomide or lenalidomideXx_NEWLINE_xXPatients who have received hydroxyurea alone or have received non-cytotoxic therapies previously for treatment of MDS or myeloproliferative neoplasm (MPN) (e.g. azacitidine, decitabine, histone deacetylase inhibitors, tyrosine kinase inhibitors, hematopoietic growth factors, interferon, lenalidomide, thalidomide) will be eligible for this trial as long as immunomodulatory drugs (e.g. lenalidomide, thalidomide) have not been used in the past 3 monthsXx_NEWLINE_xXThe development of erythema nodosum if characterized by a desquamating rash while taking thalidomide, lenalidomide or similar drugs in the pastXx_NEWLINE_xXMust have undergone prior treatment with at least 2 cycles of lenalidomide and at least 2 cycles of a proteasome inhibitor (either in separate regimens or within the same regimen)Xx_NEWLINE_xXHypersensitivity to thalidomide, lenalidomide, or dexamethasone (such as Steven Johnson Syndrome). Hypersensitivity, such as rash, that can be medically managed is allowableXx_NEWLINE_xXPregnant or lactating females. Because there is a potential risk for adverse events nursing infants secondary to treatment of the mother with carfilzomib in combination with lenalidomide. These potential risks may also apply to other agents used in this studyXx_NEWLINE_xXDisease progression as defined by International Myeloma Working (IMW) Criteria on the combination of carfilzomib, lenalidomide and dexamethasone (patients with progression on lenalidomide maintenance after completion of carfilzomib, lenalidomide and dexamethasone combination therapy will be eligible)Xx_NEWLINE_xXPrior dose limiting toxicity from carfilzomib or lenalidomideXx_NEWLINE_xXPatients must be on standard of care lenalidomide maintenance therapy for at least 6 months at the time of study enrollment.Xx_NEWLINE_xXLenalidomide within 1 day prior to leukapheresisXx_NEWLINE_xXPatients must have prior treatment with >= 2 cycles of lenalidomide and >= 2 cycles of bortezomib (either in separate regimens or as part of the same regimen) (primary refractory of subjects refractory to the most recent regimen are eligible)Xx_NEWLINE_xXHypersensitivity to previous lenalidomide or thalidomideXx_NEWLINE_xXMale subjects must agree not to donate semen or sperm while taking lenalidomide and/or carfilzomib and 28 days after the last lenalidomide/carfilzomib doseXx_NEWLINE_xXFor subjected enrolled in the United States, no coverage or not-acceptable by patient co-pay for lenalidomideXx_NEWLINE_xXPregnant females; (lactating females must agree not to breastfeed while taking lenalidomide or romidepsin)Xx_NEWLINE_xXPrior use of lenalidomide if discontinued due to toxicityXx_NEWLINE_xXHistory of hypersensitivity to lenalidomideXx_NEWLINE_xXPatients who are post auto-SCT as primary therapy must have received maintenance therapy with lenalidomideXx_NEWLINE_xXPatients must be registered within 6 months of last dose of lenalidomideXx_NEWLINE_xXAny prior use of thalidomide or pomalidomideXx_NEWLINE_xXAll subjects must have received prior treatment with a lenalidomide containing regimen for at least 2 consecutive cycles.Xx_NEWLINE_xXPatients may have received prior ibrutinib, lenalidomide, rituximab, and/or bortezomib either alone or in combinationXx_NEWLINE_xXKnown hypersensitivity to thalidomide, lenalidomide or rituximab; including the development of erythema nodosum if characterized by a desquamating rash while taking thalidomideXx_NEWLINE_xXHypersensitivity to thalidomide, lenalidomide or pomalidomideXx_NEWLINE_xXKnown hypersensitivity to thalidomide or lenalidomide (if applicable)Xx_NEWLINE_xXHave discontinued lenalidomide due to any treatment-related adverse event or be refractory to any dose of lenalidomide. Refractory to lenalidomide is defined as either, participants whose disease progresses within 60 days of lenalidomide, or participants whose disease is nonresponsive while on any dose of lenalidomide. Nonresponsive disease is defined as either failure to achieve at least an minimal response (MR) or development of progressive disease (PD) while on lenalidomideXx_NEWLINE_xXKnown hypersensitivity to thalidomide or lenalidomide.Xx_NEWLINE_xXLactating females are not eligible unless they have agreed not to breastfeed their infants while receiving protocol therapy and for 28 days after the last dose of lenalidomideXx_NEWLINE_xXKnown hypersensitivity to thalidomide or lenalidomideXx_NEWLINE_xXAny prior use of lenalidomideXx_NEWLINE_xXAny prior use of lenalidomide.Xx_NEWLINE_xXPatients may have received lenalidomide and/or dexamethasoneXx_NEWLINE_xXKnown hypersensitivity to thalidomide or lenalidomide.Xx_NEWLINE_xXConfirmed relapsed or refractory multiple myeloma (MM) or plasma cell leukemia (PCL); patients should have received at least 1 prior treatment regimen; prior treatment must have included at least one full cycle of a proteasome inhibitor (e.g., bortezomib) and at least one full cycle of an immunomodulatory (IMiD) (e.g., thalidomide, lenalidomide or pomalidomide); patients who have had prior ARRY-520 and carfilzomib will be allowed in the dose escalation phase, however prior ARRY-520 and carfilzomib will be excluded in the dose expansion cohort 1 of part A; there will be 2 cohorts in the dose expansion of part A: cohort 1 will be patients who are carfilzomib sensitive; cohort 2 will be patients who are carfilzomib refractoryXx_NEWLINE_xXPrior therapy with thalidomide and lenalidomide is allowedXx_NEWLINE_xXPrior treatment with Lenalidomide permitted if:Xx_NEWLINE_xXSubject did not receive more than 9 cycles of Lenalidomide and had at least 9 months between the last dose of Lenalidomide and progressionXx_NEWLINE_xXPatient has any prior use of lenalidomideXx_NEWLINE_xXMust have received at least one (1) prior line of systemic treatment that has included either lenalidomide or thalidomide.Xx_NEWLINE_xXPatients with MDS should have failed prior therapy with a hypomethylating agent or, if associated with a 5q- chromosomal abnormality, lenalidomide. NOTE: Patients with 5q- unable to receive or intolerant to lenalidomide are also eligible.Xx_NEWLINE_xXPrevious therapy with IMiD compounds (thalidomide, lenalidomide, pomalidomide), proteasome inhibitors (bortezomib, carfilzomib), and corticosteroids must be discontinued at least 14 days before entry onto this studyXx_NEWLINE_xXKnown hypersensitivity to thalidomide, lenalidomide, azacitidine, or mannitolXx_NEWLINE_xXThe development of erythema nodosum if characterized by a desquamating rash while taking thalidomide or lenalidomide drugsXx_NEWLINE_xXPrevious inability to tolerate full-dose lenalidomide, adjusted to creatinine clearance (CrCl) according to Cockroft-Gault at the time of previous lenalidomide treatment (25 mg day 1-21 every 28 days if CrCl >= 60 ml/min, 10 mg lenalidomide days (d) 1-21 every 28 days if CrCl < 60 mL/min but >= 30 mL/min, lenalidomide 15 mg every 48 hours (h) d1-21 every 28 days if CrCl < 30 mL/min but not requiring dialysis, lenalidomide 5 mg daily, day 1-21 every 28 days if CrCl < 30 mL/min and requiring dialysisXx_NEWLINE_xXHistory of intolerance or resistance to lenalidomideXx_NEWLINE_xXKnown hypersensitivity to thalidomide or lenalidomide (if applicable)Xx_NEWLINE_xXAny prior use of lenalidomideXx_NEWLINE_xXActive infection at the start of lenalidomideXx_NEWLINE_xXMust agree to receive counseling related to teratogenic and other risks of lenalidomide.Xx_NEWLINE_xXSystemic infection that has not resolved > 2 months prior to initiating lenalidomideXx_NEWLINE_xXPrior therapy with lenalidomide.Xx_NEWLINE_xXSystemic infection that has not resolved > 2 months prior to initiating lenalidomide treatment in spite of adequate anti-infective therapyXx_NEWLINE_xXPrior therapy with lenalidomide.Xx_NEWLINE_xXReceived prior treatment for MDS with lenalidomide or hypomethylating agents (HMAs).Xx_NEWLINE_xXParticipants in the combination therapy arms must be eligible to receive pomalidomide/dexamethasone, bortezomib/dexamethasone or lenalidomide/dexamethasone or other approved agents per current prescribing information for MM.Xx_NEWLINE_xXParticipants who will receive combination therapy with Pomalidomide/Dexamethasone must have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapyXx_NEWLINE_xXHave known hypersensitivity to thalidomide or lenalidomideXx_NEWLINE_xXPatients with known hypersensitivity to thalidomide or lenalidomide or pomalidomideXx_NEWLINE_xXTreatment with investigational GVHD prophylactic agents (eg, CCR5 inhibitors; lenalidomide; and/or bortezomib) within the 7 days prior to the 1st dose of neihulizumabXx_NEWLINE_xXELIGIBILITY FOR VACCINE AND LENALIDOMIDE ADMINISTRATION (PROTOCOL ENTRY)Xx_NEWLINE_xXKnown hypersensitivity to thalidomide or lenalidomideXx_NEWLINE_xXRefractory to lenalidomide in the most recent line of therapy, as defined by the International Myeloma Consensus Panel criteria as failure to achieve minimal response or development of progressive disease while on lenalidomide or within 30 days of lenalidomide therapyXx_NEWLINE_xXPatients who were previously exposed and who developed severe adverse events, hypersensitivity or desquamating rash to either thalidomide or lenalidomideXx_NEWLINE_xXHistory of hypersensitivity to IMiDs® (lenalidomide, pomalidomide, thalidomide).Xx_NEWLINE_xXIf previously received lenalidomide, demonstration of clinical response of any duration or stable disease with progression-free interval of ?6 months from start of that therapy.Xx_NEWLINE_xXKnown hypersensitivity to thalidomide or lenalidomide (if applicable)Xx_NEWLINE_xXPatients must have received previous bortezomib-containing and lenalidomide-containing regimens (or thalidomide where lenalidomide is not available)Xx_NEWLINE_xXReceived at least 2 cycles of a bortezomib-containing regimen and 2 cycles of a lenalidomide-containing regimen, unless intolerant to these agents (defined as requiring discontinuation due to toxicity).Xx_NEWLINE_xXPatients must have received at least 2 prior treatment regimens, including bortezomib and an IMiD (e.g., lenalidomide, thalidomide, pomalidomide). Induction therapy and stem cell transplant ± maintenance are to be considered as a single regimen.Xx_NEWLINE_xXLenalidomide must have been used for at least 6 months after autologous hematopoietic stem cell transplantation with the current dose of lenalidomide 15 mg/day or lessXx_NEWLINE_xXKnown hypersensitivity to thalidomide or lenalidomideXx_NEWLINE_xXLenalidomide, thalidomide and pomalidomideXx_NEWLINE_xXRelapsed myeloma that previously became refractory to lenalidomide, after initial response of partial response or better to the drug; refractory is defined as progression on treatment with a dose of at least 10 mg daily for lenalidomide; greater than or equal to 180 days must have elapsed since previous lenalidomide therapy was stoppedXx_NEWLINE_xXSubjects must have received prior treatment with bortezomib, and either thalidomide or lenalidomideXx_NEWLINE_xXPrior treatment with lenalidomideXx_NEWLINE_xXPatients must be suitable for treatment or re-treatment with lenalidomide & dexamethasone; Note: patients previously treated with lenalidomide & dexamethasone are eligible to participate in the trialXx_NEWLINE_xXAll patients must agree to follow the requirements for lenalidomide counseling, pregnancy testing and birth control; for women of childbearing potential (WOCBP) this includes pregnancy testing prior to prescribing lenalidomide and to either commit to continued\r\nabstinence from heterosexual intercourse or begin acceptable methods of birth control for 28 days prior to prescribing lenalidomide, during therapy and for 28 days after the last dose of lenalidomide; WOCBP must also agree to ongoing pregnancy testing; men must agree to use a latex condom during sexual contact with a WOCBP even if they have had a successful vasectomy and must agree not to donate semen during study drug therapy and for a period of time after therapy; all patients must abstain from donating blood, agree not to share lenalidomide with others and be counseled about the risks of lenalidomideXx_NEWLINE_xXKnown hypersensitivity to lenalidomide or thalidomideXx_NEWLINE_xXPrior Lenalidomide exposure is permitted only if the subject did not discontinue Lenalidomide due to a Grade ?3 related Adverse Event (AE)Xx_NEWLINE_xXAll subjects must have received at least 2 consecutive cycles of prior treatment that included lenalidomide and bortezomibXx_NEWLINE_xXAll subjects must have failed treatment with both lenalidomide and bortezomib in one of the following ways: 1) Documented progressive disease on or within 60 days of completing treatment with lenalidomide and/or bortezomib, or 2) In case of prior response [? partial response (PR)] to lenalidomide or bortezomib, subjects must have relapsed within 6 months after stopping treatment with lenalidomide and/or bortezomib-containing regimens, or 3) Subjects who have not had a ? minimal response (MR) and have developed intolerance/toxicity after a minimum of two cycles of lenalidomide- and/or bortezomib-containing regimenXx_NEWLINE_xXHypersensitivity to thalidomide, lenalidomide, or dexamethasoneXx_NEWLINE_xXPrior treatment with lenalidomide or everolimusXx_NEWLINE_xXIf previously treated with a lenalidomide and dexamethasone (len/dex) combination:Xx_NEWLINE_xXDiscontinuation of previous lenalidomide or dexamethasone due to intolerance; subjects intolerant to bortezomib are not excludedXx_NEWLINE_xXSubjects must agree to receive counseling related to pregnancy precautions, teratogenic and other risks of lenalidomideXx_NEWLINE_xXPrior Therapy with thalidomide, lenalidomide or pomalidomideXx_NEWLINE_xXPrior lenalidomide therapy.Xx_NEWLINE_xXHypersensitivity to recombinant proteins or excipients in elotuzumab, lenalidomide, or dexamethasone.Xx_NEWLINE_xXPatients must be suitable for treatment with lenalidomide & dexamethasone.Xx_NEWLINE_xXPrior therapy with histone deacetylase (HDAC) inhibitors or immunomodulatory drugs (IMDs) (lenalidomide or thalidomide)Xx_NEWLINE_xXPatients may have had prior treatment for myelodysplastic syndrome (MDS) or AML, including prior lenalidomide for MDS or AML or another conditionXx_NEWLINE_xXKnown hypersensitivity to thalidomide or lenalidomide (if applicable)Xx_NEWLINE_xXBoth men and women in the lenalidomide combination arm (Cohort D) must adhere to the guidelines of the RevAssist program (United States participants) or, if not using commercial supplies, must adhere to the Lenalidomide Pregnancy Risk Minimisation Plan as outlined in the Study Manual.Xx_NEWLINE_xXFor participant in the lenalidomide combination arm, demonstrated hypersensitivity (example, angioedema, Stevens-Johnson syndrome, toxic epidermal necrolysis) to lenalidomide.Xx_NEWLINE_xXKnown hypersensitivity to thalidomide or lenalidomideXx_NEWLINE_xXPlatelet count =< 50 x 10^9/L untransfused of at least 2 weeks duration, secondary to prior chemotherapy; if there is a platelet count of > or = 50 x 10^9/L after a transfusion, that value will be discounted; this may include a combination regimen including lenalidomide; these regimens will include dexamethasone, cyclophosphamide, etoposide, cisplatin (DCEP), Velcade with Doxil, Cytoxan and/or lenalidomide; patients who have thrombocytopenia (CIT) from lenalidomide or from radiation therapy alone will not be allowed; patients may be retreated with Nplate within 6 months of their initial response, with a different chemotherapy regimenXx_NEWLINE_xXPatients receiving maintenance therapy with myelosuppressive medications such as lenalidomide will be excludedXx_NEWLINE_xXKnown sensitivity to lenalidomide or other thalidomide derivativesXx_NEWLINE_xXLenalidomide naïve; relapsed or refractory CD20-positive follicular lymphoma (Grade 1, 2, or 3a) following at least one prior standard systemic treatment regimen including systemic chemo-, immune-; or chemo-immunotherapy and at least one prior line of salvage therapy with no prior exposure to lenalidomide, or double-refractory FL subjects with no prior exposure to lenalidomide (FL-1 cohort)Xx_NEWLINE_xXLenalidomide exposed: relapsed or refractory CD20-positive follicular lymphoma (Grade 1, 2, or 3a) previously treated with at least two cycles of lenalidomide-containing regimen (FL-2 cohort), either as a single agent or in combinationXx_NEWLINE_xXRecommended to start lenalidomideXx_NEWLINE_xX